Keuangan Gilead Sciences, Inc. (GILD)
NASDAQ · Healthcare · Drug Manufacturers - General · Karyawan: 17.000 · CEO: Daniel O'Day
- Harga
- $170,68 +3,06%
- Kapitalisasi pasar
- $212 M
- Nilai perusahaan
- $231 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-30
- Laporan berikutnya
- 2027-02-09 Estimasi EPS: $1,39
Pendapatan (TTM)$31 M+6,5% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)-4,4%-40,4 poin vs tahun laluLaba operasional: -$1,36 M
Laba bersih (TTM)-$3,86 M-147,6% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$14 M+53,2% vs tahun laluCapex: $442 jt
EPS dilusian (TTM)-$3,16-149,0% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$19,8 M-12,5% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $212 M EV $231 M
- Pendapatan
- $31 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +6% Konsensus FY2026
- Margin laba
- -12,5% Laba bersih / pendapatan, TTM
- P/E
- -55,1× Forward -213,4× (FY2026)
- P/S
- 6,8× Harga / penjualan, TTM
- EV / EBITDA
- 281,2× TTM
- Arus kas bebas
- $14 M 12 bulan terakhir
- Laba bersih
- -$3,86 M 12 bulan terakhir
- Estimasi pendapatan
- $31,2 M Konsensus FY2026
- Laba
- 2027-02-09 Estimasi pendapatan: $8,28 M
- Dividen
- $3,25 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-29): pendapatan melampaui 6,3%, EPS melampaui 16,4%Pendapatan $8,3 M vs $7,81 M yang diharapkan (+6,3%); EPS $2,55 vs $2,19 (+16,4%).
- Pertumbuhan pendapatan menguat: 6,8% yoyPendapatan Q3 '26: $8,3 M, rata-rata empat kuartal sebelumnya: 5,6%.
- Margin operasional -4,4% (TTM), dibanding tahun lalu: -40,4 poinLaba operasional tumbuh -112,9%, pendapatan tumbuh 6,5%.
- Capex: 1,4% dari pendapatan (tahun lalu 1,7%)$442 jt diinvestasikan dalam 4 kuartal terakhir (-12,5% dibanding tahun sebelumnya). Arus kas bebas: $14 M.
- $5,48 M dikembalikan ke pemegang saham = 39,0% dari arus kas bebasBuyback: $1,37 M (tahun lalu $2,04 M), dividen: $4,1 M, kompensasi saham: $464 jt (TTM).
- Jumlah saham dilusian turun dalam setahun: 0,2%Saham dilusian pada Q3 '26: 1,25 M, setahun sebelumnya: 1,25 M.
- Utang neto: $19,8 MKas + investasi jangka pendek: $6,44 M, utang termasuk sewa: $26,2 M; tahun lalu utang neto: $17,6 M.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $8,3 M | $7,77 M | +6,8% |
| Margin kotor | 81,1% | 79,8% | +1,3 poin |
| Laba operasional | $3,46 M | $3,33 M | +4,1% |
| Margin operasional | 41,7% | 42,8% | -1,1 poin |
| Laba bersih | $2,43 M | $3,05 M | -20,4% |
| EPS dilusian | $1,94 | $2,43 | -20,2% |
| Arus kas operasional | $5,04 M | $4,11 M | +22,6% |
| Capex | $237 jt | $147 jt | +61,2% |
| Arus kas bebas | $4,8 M | $3,96 M | +21,2% |
| R&D | $1,61 M | $1,35 M | +19,5% |
| Kompensasi berbasis saham | $234 jt | $230 jt | +1,7% |
Dilaporkan vs konsensus
2026-10-29| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $8,3 M | $7,81 M | +6,3% |
| EPS (basis konsensus) | $2,55 | $2,19 | +16,4% |
Dari laporan 2026-10-29 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Products, Other HIV | $6,25 M | +18,4% | 84,2% | – | – | |
| Total HIV | – | – | – | – | – | |
| Cell Therapy Products, Total Cell Therapy Product Sales | $415 jt | -19,4% | 5,6% | – | – | |
| Total Liver Disease | – | – | – | – | – | |
| Total Oncology | – | – | – | – | – | |
| Veklury | $86 jt | -69,0% | 1,2% | $464 jt | -62,9% | |
| Trodelvy | $506 jt | +41,7% | 6,8% | – | – | |
| Other Products, Total Other product sales | $167 jt | -9,2% | 2,2% | – | – | |
| Total Other | – | – | – | – | – | |
| Royalty, contract and other revenues | – | – | – | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $6,36 M | +20,5% | 76,7% | $22,5 M | +8,5% | |
| Europe | $1,07 M | -31,5% | 12,8% | $4,77 M | -4,7% | |
| Other International | $872 jt | -6,5% | 10,5% | $3,45 M | -1,9% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $14,5 M
- Capex
- -$442 jt
- Buyback
- -$1,37 M
- Dividen
- -$4,1 M
- Akuisisi
- -$628 jt
- Utang neto diterbitkan
- $1,28 M
- Kompensasi berbasis saham
- $464 jt
- Arus kas bebas
- $14 M
- Dikembalikan ke pemegang saham / FCF
- 39,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -55,1× | 63,4× | 14,6× – 243,1× |
| EV / EBITDA | 281,2× | 15,6× | 9,9× – 29,7× |
| EV / Penjualan | 7,5× | 4,7× | 4,1× – 5,8× |
| Harga / FCF | 15,1× | 12,5× | 8,4× – 16,1× |
| Harga / Nilai buku | 16,3× | 5,3× | 4,3× – 6,7× |
| Imbal hasil FCF | 6,6% | 8,4% | 6,2% – 11,8% |
| Imbal hasil modal yang diinvestasikan | -3,2% | 11,6% | 2,4% – 20,3% |
| Imbal hasil ekuitas | -21,7% | 23,2% | 2,5% – 37,5% |
Analis
Target konsensus $163,67 (-4,1%)
rentang $126,00 – $195,00 · peringkat Buy
Beli kuat0
Beli38
Tahan19
Jual1
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $31,2 M | +6,0% | -$0,80 | -111,8% | -213,4× | 11 |
| FY2027 | $33,4 M | +7,0% | $10,07 | +1.359,8% | 16,9× | 16 |
| FY2028 | $34,8 M | +4,0% | $10,78 | +7,0% | 15,8× | 10 |
| FY2029 | $37,3 M | +7,4% | $12,20 | +13,1% | 14,0× | 4 |
| FY2030 | $39,6 M | +6,1% | $13,35 | +9,4% | 12,8× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 275 angka yang ditandai Gilead Sciences, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $934 jt | $808 jt | +15,6% | $715 jt | $833 jt | -14,2% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $5,01 M | $5,1 M | -1,7% | $4,91 M | $4,42 M | +11,2% |
| Accounts Receivable, Allowance for Credit Loss, Current | $42 jt | $41 jt | +2,4% | $41 jt | $52 jt | -21,2% |
| Accounts Receivable, before Allowance for Credit Loss, Current | $5,96 M | $5,99 M | -0,6% | $5,9 M | $5,32 M | +10,8% |
| Accrued Income Taxes, Current | $92 jt2025-12-31 | $1,65 M | -94,4% | $92 jt | $1,65 M | -94,4% |
| Accrued Income Taxes, Noncurrent | $974 jt | $866 jt | +12,5% | $896 jt | $830 jt | +8,0% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $3 M | $2,69 M | +11,4% | $2,7 M | $2,47 M | +9,1% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $89 jt | $36 jt | +147,2% | $39 jt | $132 jt | -70,5% |
| Additional Paid in Capital | $9,84 M | $8,68 M | +13,4% | $8,93 M | $7,7 M | +16,0% |
| Advertising Expense | – | – | – | $1 M | $869 jt | +15,1% |
| Amortization | $608 jt | $596 jt | +2,0% | $2,39 M | $2,39 M | +0,2% |
| Amortization of Intangible Assets | – | – | – | $2,4 M | $2,4 M | 0,0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1 jt | 3 jt | -66,7% | 2 jt | 5 jt | -60,0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $234 jt | $231 jt | +1,3% | $899 jt | $834 jt | +7,8% |
| Assets | $51,4 M | $58,5 M | -12,2% | $59 M | $59 M | 0,0% |
| Assets, Current | $16,6 M | $17,9 M | -7,4% | $18,3 M | $19,2 M | -4,3% |
| Assets, Fair Value Disclosure | $6,48 M | – | – | $6,97 M2020-12-31 | $11 M | -36,9% |
| Buildings and Improvements, Gross | $4,62 M2025-12-31 | $4,54 M | +1,8% | $4,62 M | $4,54 M | +1,8% |
| Capitalized Computer Software, Gross | $666 jt2025-12-31 | $692 jt | -3,8% | $666 jt | $692 jt | -3,8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $6,44 M | $7,33 M | -12,2% | $7,56 M | $9,99 M | -24,3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $3,26 M | $2,19 M | +49,0% | -$2,43 M | $3,91 M | -162,2% |
| Common Stock, Dividends, Per Share, Declared | $0,82 | $0,79 | +3,8% | $3,16 | $3,08 | +2,6% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 5,6 M | 5,6 M | 0,0% | 5,6 M | 5,6 M | 0,0% |
| Common Stock, Shares, Issued | 1,24 M | 1,24 M | -0,1% | 1,24 M | 1,25 M | -0,4% |
| Common Stock, Shares, Outstanding | 1,24 M | 1,24 M | -0,1% | 1,24 M | 1,25 M | -0,4% |
| Common Stock, Value, Issued | $1 jt | $1 jt | 0,0% | $1 jt | $1 jt | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $02025-12-31 | $0 | – | $0 | $0 | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $2,42 M | $3,11 M | -22,0% | $8,42 M | $584 jt | +1.341,4% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $2,19 M2025-12-31 | $1,84 M | +18,7% | $8,42 M | $584 jt | +1.341,4% |
| Construction in Progress, Gross | $745 jt2025-12-31 | $501 jt | +48,7% | $745 jt | $501 jt | +48,7% |
| Contract with Customer, Asset, after Allowance for Credit Loss | $732 jt | $695 jt | +5,3% | $629 jt | $277 jt | +127,1% |
| Contract with Customer, Liability | $57 jt | $56 jt | +1,8% | $48 jt | $58 jt | -17,2% |
| Contract with Customer, Performance Obligation Satisfied in Previous Period | $146 jt | $148 jt | -1,4% | $612 jt | $727 jt | -15,8% |
| Contract with Customer, Refund Liability, Current | $321 jt2025-12-31 | $321 jt | 0,0% | $321 jt | $321 jt | 0,0% |
| Cost of Goods and Services Sold | $1,57 M | $1,57 M | +0,1% | $6,23 M | $6,25 M | -0,3% |
| Costs and Expenses | $4,84 M | $4,44 M | +8,9% | $19,4 M | $27,1 M | -28,3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $820 jt | $1,5 M | -45,2% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $256 jt | $519 jt | -50,7% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $51 jt | $39 jt | +30,8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $1 jt2026-03-31 | – | – | $11 jt | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $4 jt2026-03-31 | – | – | $1 jt | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | $02025-09-30 | – | – | $2 jt2023-12-31 | $6 jt | -66,7% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $4 jt2026-03-31 | – | – | $32 jt | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $982 jt2026-03-31 | – | – | $2,93 M | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $15 jt2026-03-31 | – | – | $70 jt | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | – | – | – | $624 jt2023-12-31 | $705 jt | -11,5% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | – | – | – | $8 jt2023-12-31 | $12 jt | -33,3% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $669 jt2026-03-31 | – | – | $724 jt | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | – | – | – | $2 jt2023-12-31 | $22 jt | -90,9% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $02025-09-30 | – | – | $2 jt2023-12-31 | $6 jt | -66,7% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $4 jt2026-03-31 | – | – | $32 jt | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $979 jt2026-03-31 | – | – | $2,94 M | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $15 jt2026-03-31 | – | – | $70 jt | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | – | – | – | $1,35 M2023-12-31 | $1,91 M | -29,2% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | – | – | – | $10 jt2023-12-31 | $34 jt | -70,6% |
| Debt, Current | $2,42 M | $2,81 M | -13,9% | $2,81 M | $1,82 M | +54,7% |
| DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss | $1 M2026-03-31 | – | – | $3,03 M | $0 | – |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterest | $997 jt2026-03-31 | – | – | $3,04 M | – | – |
| Deferred Compensation Arrangement with Individual, Compensation Expense | – | – | – | $200 jt | $204 jt | -2,0% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-01